<DOC>
	<DOCNO>NCT01813812</DOCNO>
	<brief_summary>This multicenter , double-blinded , double-dummy , active-controlled , randomize , Phase III clinical trial evaluate efficacy safety DA-6034 demonstrate non-inferiority DA-6034 compare Rebamipide patient acute chronic gastritis . Subjects receive 45mg , 90mg DA-6034 300mg Rebamipide , two tablet , three time day two week .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety DA-6034 Demonstrate Non-inferiority DA-6034</brief_title>
	<detailed_description />
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Gastritis , Atrophic</mesh_term>
	<mesh_term>Rebamipide</mesh_term>
	<criteria>Diagnosed acute gastritis chronic gastritis 1 erosion find gastroscope examination Age : 20≤age≤75 A patient peptic ulcer gastroesophageal reflux disease . Received medication include nonsteroid antiinflammatory drug 2 week initiation Had surgery regard gastroesophageal A patient ZollingerEllison syndrome Had medical history malignant tumor A patient currently take antithrombotic drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>